ISSN: 2157-2518
Journal of Carcinogenesis & Mutagenesis

OPEN ACCESS Freely available online

Commentary

Diagnostic Approaches in Renal Cell Carcinoma

Peter Mulders*

Department of Urology and Urological Surgery, University Medical Centre Mannheim, Mannheim, Germany

DESCRIPTION

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer, accounting for approximately 90% of cases. It arises from the cells lining the tubules of the kidney and has various subtypes with distinct histological and molecular characteristics. RCC poses a significant health burden globally and is associated with a high mortality rate. This article provides a comprehensive analysis of renal cell carcinoma, including its epidemiology, risk factors, clinical presentation, diagnostic approaches, treatment options, and emerging therapeutic strategies.

Epidemiology and risk factors

RCC affects both men and women, with a higher incidence in males. It typically occurs in individuals aged 50 to 70 years, although it can occur at any age. Several risk factors are associated with the development of RCC, including tobacco smoking, obesity, hypertension, family history of kidney cancer, exposure to certain chemicals, and certain genetic syndromes, such as von Hippel-Lindau disease and hereditary papillary renal cell carcinoma.

Clinical presentation

RCC often presents with nonspecific symptoms, making early detection challenging. Common clinical manifestations include hematuria (blood in urine), flank pain, palpable mass in the abdomen or flank, unexplained weight loss, and fatigue. In advanced stages, RCC can metastasize to distant organs, leading to additional symptoms, such as bone pain, cough, and neurological abnormalities.

Diagnostic approaches

The diagnosis of RCC involves a combination of imaging studies, laboratory tests, and histopathological examination. Imaging modalities, including Computed Tomography (CT) scans, Magnetic Resonance Imaging (MRI), and ultrasound, are crucial for identifying the presence, location, and extent of the tumor [1]. Blood tests, such as renal function tests and measurement of specific tumor markers (e.g., serum creatinine, lactate dehydrogenase, and von Hippel-Lindau disease mutations), help evaluate kidney function and provide prognostic information. Confirmation of RCC is achieved through histopathological examination of the tumor tissue obtained *via* biopsy or surgical resection [2].

Treatment options

The management of RCC depends on various factors, including the stage of the disease, tumor characteristics, overall health status of the patient, and patient preferences. Treatment options for RCC include surgery, targeted therapy, immunotherapy, and radiation therapy.

Surgery: Surgical intervention, typically in the form of radical nephrectomy or partial nephrectomy, is the primary treatment for localized RCC. In selected cases, minimally invasive techniques such as laparoscopic or robotic-assisted surgery may be employed.

Targeted therapy: Targeted therapy drugs, such as Tyrosine Kinase Inhibitors (TKIs) and immune checkpoint inhibitors, have revolutionized the treatment of advanced and metastatic RCC. These medications inhibit specific molecules or pathways involved in tumor growth and immune system regulation [3].

Immunotherapy: Immune checkpoint inhibitors, including Programmed cell Death protein 1 (PD-1) inhibitors and Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4) inhibitors, have demonstrated significant clinical benefits in the treatment of advanced RCC. These agents enhance the immune system's ability to recognize and eliminate cancer cells [4].

Radiation therapy: Radiation therapy may be utilized as a primary treatment for localized RCC or as a palliative treatment to alleviate symptoms in advanced stages. It involves the use of high-energy radiation to target and destroy cancer cells [5].

Correspondence to: Peter Mulders, Department of Urology and Urological Surgery, University Medical Centre Mannheim, Mannheim, Germany, E-mail: peter@gte2.com

Received: 24-May-2023, Manuscript No. JCM-23-22210; **Editor assigned:** 26-May-2023, Pre QC No. JCM-23-22210 (PQ); **Reviewed:** 12-Jun-2023, QC No. JCM-23-22210; **Revised:** 20-Jun-2023, Manuscript No. JCM-23-22210 (R); **Published:** 28-Jun-2023, DOI: 10.35248/2157-2518.23.14.419.

Citation: Mulders P (2023) Diagnostic Approaches in Renal Cell Carcinoma. J Carcinog Mutagen. 14:419.

Emerging therapeutic strategies

Advancements in our understanding of the molecular mechanisms and genetic alterations in RCC have paved the way for novel therapeutic strategies.

Targeting angiogenesis: Angiogenesis, the process of new blood vessel formation, plays a crucial role in RCC growth and progression. Drugs targeting Vascular Endothelial Growth Factor (VEGF), such as bevacizumab, have shown efficacy in inhibiting angiogenesis and improving outcomes in RCC [6].

Immunotherapy combinations: Combining immune checkpoint inhibitors with other immunotherapeutic agents or targeted therapies has demonstrated promising results in clinical trials, leading to improved outcomes in advanced RCC [7].

Genetic testing and precision medicine: Genetic testing enables the identification of specific genetic alterations in RCC, allowing for the development of personalized treatment approaches targeting specific molecular pathways or mutations [8].

Renal cell carcinoma is the most common form of kidney cancer, with distinct subtypes and diverse clinical presentations [9]. Early diagnosis and appropriate treatment are crucial for improving patient outcomes. Advances in targeted therapy and immunotherapy have significantly transformed the management of advanced RCC. Additionally, emerging therapeutic strategies, such as targeting angiogenesis and combining immunotherapeutic agents, offer potential avenues for future treatment approaches [10]. Continued research efforts focusing on understanding the molecular basis of RCC and identifying novel therapeutic targets will contribute to improved patient care and outcomes in this challenging disease.

REFERENCES

1. Baidoshvili A, Bucur A, van Leeuwen J, van der Laak J, Kluin P, van Diest PJ. Evaluating the benefits of digital pathology implementation: Time savings in laboratory logistics. Histopathology. 2018; 73(5):784-794.
2. Shmatko A, Ghaffari Laleh N, Gerstung M, Kather JN. Artificial intelligence in histopathology: Enhancing cancer research and clinical oncology. Nat Cancer. 2022; 3(9):1026-1038.
3. Niazi MK, Parwani AV, Gurcan MN. Digital pathology and artificial intelligence. Lancet Oncol. 2019; 20(5):e253-261.
4. Colling R, Pitman H, Oien K, Rajpoot N, Macklin P, Bury J, et al. Artificial intelligence in digital pathology: A roadmap to routine use in clinical practice. J Pathol. 2019; 249(2):143-150.
5. Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, et al. Management of renal masses and localized renal cancer: Systematic review and meta-analysis. J Urol. 2016; 196(4): 989-999.
6. Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009; 181(5):2033-2036.
7. Johnson DC, Vukina J, Smith AB, Meyer AM, Wheeler SB, Kuo TM, et al. Preoperatively misclassified, surgically removed benign renal masses: A systematic review of surgical series and United States population level burden estimate. J Urol. 2015; 193(1):30-35.
8. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: An analysis of pathological features related to tumor size. J Urol. 2003; 170(6):2217-2220.
9. Bhindi B, Thompson RH, Lohse CM, Mason RJ, Frank I, Costello BA, et al. The probability of aggressive versus indolent histology based on renal tumor size: Implications for surveillance and treatment. Eur Urol. 2018; 74(4):489-497.
10. Patel HD, Semerjian A, Gupta M, Pavlovich CP, Johnson MH, Gorin MA, et al. Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature. Urol Oncol. 2019; 37(8):519-524.